Karuna Therapeutics financials at a glance

+ Portfolio

The revenue of Karuna Therapeutics is reported as 0.00065 billion Dollars in the fiscal year 2023. The earnings were -11.73 Dollars per share in 2023, which was 34.21 lower than 2022. And about -0.35192 billion Dollars are reported as free cash flow in the financials of Karuna Therapeutics 2023. No dividends were paid to the shareholders of the Karuna Therapeutics stock NasdaqGM:KRTX in the financial year 2023.

$0.65M

Revenue

$-11.73

Earnings Per Share

100.00%

Gross Margin %

$-,319.90M

Free Cash Flow

Revenue

0.65

Earnings Per Share

-11.73

Gross Margin %

100.00

Free Cash Flow

-,319.90

Financials

Year	Year	TTM	2023	2022	2021	2020	2019
Rev.	Revenue	N/A	$0.65M	$10.64M	$36.96M	$0.00M	$0.00M
GM %	Gross Margin %	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-10.97	$-11.73	$-8.74	$-4.94	$-2.59	$-3.68
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	38.15M	34.52M	29.81M	27.02M	26.08M
OCF	Operating Cash Flow	N/A	$-,349.00M	$-,228.01M	$-,100.88M	$-69.86M	$-30.92M
FCF	Free Cash Flow	N/A	$-,319.90M	$-,228.92M	$-,103.95M	$-70.28M	$-31.04M
FCFS	Free Cash Flow Per Share	$-9.85	$-10.52	$-7.24	$-3.57	$-2.66	$-2.60

Karuna Therapeutics financials at a glance

Financials

Discover